Organizing pneumonia resembling disease progression in a non-small-cell lung cancer patient receiving ceritinib: A case report
Rationale:
Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK), a distinct molecular entity, is highly sensitive to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib or ceritinib. Interstitial lung disease is a rare (1.2%) pulmonary toxicity that can result from ALK TKIs, however, organizing pneumonia has not been reported to date.
Patient concerns:
A 45-year-old Korean female with ALK-rearranged metastatic lung adenocarcinoma underwent ceritinib treatment and exhibited a partial response, until she developed organizing pneumonia resembling disease progression.
Diagnoses:
Multiple rebiopsies confirmed the involvement of organizing pneumonia in the pathology.
Interventions:
Ceritinib was stopped and the patient was treated with intravenous antibiotics followed by oral antibiotics for two weeks.
Outcomes:
After recovering from organizing pneumonia, ceritinib was successfully rechallenged and the patient attained a complete response.
Lessons:
When a new mass-like lesion develops in the lungs of responding patients, benign lung conditions, including organizing pneumonia should be considered in differential diagnoses.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Internal Medicine | Interstitial Lung Disease | Lessons | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Oral Cancer | Pathology | Pneumonia | Toxicology